Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bepranemab in Prodromal to Mild Alzheimer's Disease
NCT04867616Phase 2Completed
- Sponsor
- UCB
- Start
- Jun 2021
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of Bepranemab in Alzheimer's disease (AD) (3 arms), sponsored by UCB. Primary endpoint: Clinical Dementia Rating Scale Sum of Boxes at 80 weeks. Started Jun 2021; status: completed.
02
Drugs
Bepranemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04867616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04867616.